12:00 AM
 | 
Feb 07, 2011
 |  BioCentury  |  Strategy

Networked in China

How small biotechs Ligand, Harbor BioSciences found partners in China

Recent China-focused deals by Ligand Pharmaceuticals Inc. and Harbor BioSciences Inc. provide a roadmap for small biotechs looking to execute a China strategy. The key is personal networking.

In January, Ligand granted Chiva Pharmaceuticals Inc. rights to develop and commercialize HBV candidate pradefovir and liver cancer candidate MB01733 in China. Pradefovir has completed Phase II studies while MB01733 has completed a Phase I/II trial in the U.S.

Chiva, an affiliate of Hainan Kaihua Pharmaceutical Co. Ltd., also received rights to Ligand's HepDirect technology to discover and develop new compounds for HBV, HCV and hepatocellular carcinoma (HCC).

Ligand will receive $1 million in payments over the next year and is eligible for more than $100 million in clinical and regulatory milestones, plus royalties. Chiva...

Read the full 613 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >